United Therapeutics Co. (NASDAQ:UTHR) Position Lessened by Weil Company Inc.

Weil Company Inc. lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 89.2% in the fourth quarter, HoldingsChannel reports. The firm owned 1,272 shares of the biotechnology company’s stock after selling 10,531 shares during the quarter. Weil Company Inc.’s holdings in United Therapeutics were worth $449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics during the fourth quarter valued at $25,000. Brooklyn Investment Group bought a new stake in United Therapeutics in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new position in United Therapeutics during the 3rd quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new position in United Therapeutics in the 3rd quarter worth about $111,000. 94.08% of the stock is currently owned by institutional investors.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $929,678.52. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nilda Mesa sold 255 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 124,164 shares of company stock valued at $45,278,893 over the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 0.2 %

NASDAQ:UTHR opened at $357.50 on Wednesday. The company has a 50-day moving average of $361.95 and a 200-day moving average of $361.11. The firm has a market cap of $15.96 billion, a price-to-earnings ratio of 15.70, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.